612 related articles for article (PubMed ID: 12698085)
21. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
22. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
[TBL] [Abstract][Full Text] [Related]
23. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
24. Sustained Epstein-Barr virus detection in paediatric liver transplantation. Insights into the occurrence of late PTLD.
D'Antiga L; Del Rizzo M; Mengoli C; Cillo U; Guariso G; Zancan L
Liver Transpl; 2007 Mar; 13(3):343-8. PubMed ID: 17154402
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
26. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
[TBL] [Abstract][Full Text] [Related]
27. Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
Roque J; Rios G; Humeres R; Volpi C; Herrera JM; Schultz M; Rios H; Rius M; Salgado C; Hepp J
Transplant Proc; 2006 Apr; 38(3):930-1. PubMed ID: 16647513
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.
Kim JM; Lee SK; Kim SJ; Joh JW; Kwon CH; Choe YH; Shin M; Kim EY; Moon JI; Jung GO; Choi GS
Transplant Proc; 2010 Apr; 42(3):895-9. PubMed ID: 20430199
[TBL] [Abstract][Full Text] [Related]
29. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
31. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation.
Heo JS; Park JW; Lee KW; Lee SK; Joh JW; Kim SJ; Lee HH; Lee DS; Choi SH; Seo JM; Choe YH
Transplant Proc; 2004 Oct; 36(8):2307-8. PubMed ID: 15561231
[TBL] [Abstract][Full Text] [Related]
32. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation.
Fukushima D; Sato K; Kawagishi N; Ohuchi N; Satomi S
Transplantation; 2015 Jan; 99(1):114-9. PubMed ID: 24846306
[TBL] [Abstract][Full Text] [Related]
34. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level.
Orii T; Ohkohchi N; Satomi S; Hoshino Y; Kimura H
Transpl Int; 2002 Nov; 15(11):529-34. PubMed ID: 12461655
[TBL] [Abstract][Full Text] [Related]
35. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.
Doesch AO; Konstandin M; Celik S; Kristen A; Frankenstein L; Sack FU; Schnabel P; Schnitzler P; Katus HA; Dengler TJ
Transpl Int; 2008 Oct; 21(10):963-71. PubMed ID: 18564989
[TBL] [Abstract][Full Text] [Related]
37. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
38. Surveillance of Epstein-Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications.
Schaffer K; Hassan J; Staines A; Coughlan S; Holder P; Tuite G; McCormick AP; Traynor O; Hall WW; Connell J
Liver Transpl; 2011 Dec; 17(12):1420-6. PubMed ID: 21837744
[TBL] [Abstract][Full Text] [Related]
39. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
Chen HS; Ho MC; Hu RH; Wu JF; Chen HL; Ni YH; Hsu HY; Jeng YM; Chang MH
J Formos Med Assoc; 2019 Sep; 118(9):1362-1368. PubMed ID: 30612881
[TBL] [Abstract][Full Text] [Related]
40. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
